Assenagon Asset Management S.A. increased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 1,386.9% in the first quarter, according to its most recent filing with the SEC. The fund owned 83,502 shares of the company’s stock after acquiring an additional 77,886 shares during the period. Assenagon Asset Management S.A. owned about 0.27% of Medpace worth $15,703,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of MEDP. Asset Management One Co. Ltd. bought a new stake in shares of Medpace during the 4th quarter worth approximately $27,000. Altshuler Shaham Ltd bought a new stake in Medpace during the 4th quarter valued at $27,000. Rockefeller Capital Management L.P. raised its position in Medpace by 361.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 143 shares of the company’s stock valued at $30,000 after purchasing an additional 112 shares in the last quarter. Picton Mahoney Asset Management bought a new stake in Medpace during the 4th quarter valued at $42,000. Finally, OLD Mission Capital LLC bought a new stake in Medpace during the 4th quarter valued at $42,000. 82.14% of the stock is owned by institutional investors.
Medpace Trading Up 2.2 %
Shares of NASDAQ:MEDP opened at $240.17 on Friday. Medpace Holdings, Inc. has a 12-month low of $141.30 and a 12-month high of $241.48. The business’s fifty day simple moving average is $212.51 and its 200-day simple moving average is $207.64. The company has a market capitalization of $7.33 billion, a PE ratio of 30.40 and a beta of 1.42.
Analyst Ratings Changes
A number of equities research analysts have weighed in on MEDP shares. Guggenheim raised Medpace from a “neutral” rating to a “buy” rating and set a $252.00 target price for the company in a research report on Monday, May 8th. 22nd Century Group reiterated an “upgrade” rating on shares of Medpace in a report on Monday, May 8th. Finally, StockNews.com upgraded Medpace from a “hold” rating to a “buy” rating in a report on Friday, May 12th. Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $241.00.
Insider Buying and Selling
In related news, CEO August J. Troendle sold 49,347 shares of the business’s stock in a transaction on Thursday, June 8th. The stock was sold at an average price of $220.85, for a total transaction of $10,898,284.95. Following the transaction, the chief executive officer now directly owns 6,233,019 shares in the company, valued at approximately $1,376,562,246.15. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO August J. Troendle sold 49,347 shares of the business’s stock in a transaction on Thursday, June 8th. The stock was sold at an average price of $220.85, for a total transaction of $10,898,284.95. Following the transaction, the chief executive officer now directly owns 6,233,019 shares in the company, valued at approximately $1,376,562,246.15. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO August J. Troendle sold 31,648 shares of the business’s stock in a transaction dated Tuesday, April 25th. The shares were sold at an average price of $221.83, for a total value of $7,020,475.84. Following the sale, the chief executive officer now owns 6,451,371 shares in the company, valued at approximately $1,431,107,628.93. The disclosure for this sale can be found here. 25.70% of the stock is owned by company insiders.
Medpace Company Profile
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Featured Articles
- Five stocks we like better than Medpace
- Tesla: Can Downgrades Make Sense After A 170% Rally?
- Buffett’s Berkshire Increases Stake In Occidental Petroleum (OXY)
- Rally Gains Momentum On Soft PCE Data
- Bank of America, JPMorgan, Goldman Sachs Set For Dividend Growth?
- SMART Global Holdings Momentum, Room To Move Higher?
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
